By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#18 – Richard Isaacson, M.D.: Alzheimer’s prevention
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:04 – 8:02
Episode Preview and Guest Introduction
Peter Attia introduces Richard Isaacson, a neurologist who directs the Alzheimer's Prevention Clinic at Cornell, and previews the topics: etiology, sex differences, risk reduction versus prevention, APOE, and the ALZU resource. He also makes a plea for funding prevention research.
- •Isaacson focuses on prevention rather than treatment, which puts him in the minority of neurologists
- •ALZU (alzu.org) is highlighted as a key resource for patients and families
- •Preview of topics: incidence vs prevalence, sex differences, APOE, risk reduction vs prevention
- •Attia says prevention research gets roughly a tenth of one percent of funding
- •Housekeeping on the weekly email and show notes
- 8:02 – 15:38
Luxury Vintage Phones and Bling Collecting
The conversation opens with Isaacson's collection of luxury vintage cell phones, including a white alligator Vertu with diamonds. He explains how he acquired the phones and what they cost, and Attia compares it to his own collecting.
- •Isaacson owns seven luxury vintage phones, including a Vertu with white alligator skin
- •He bought his first one in Vegas for $8,600 to impress a girlfriend
- •Ringtones were recorded by the London Symphony Orchestra and a Ferrari
- •The company went out of business, and he got others at auction
- •Attia mentions collecting BlackBerrys and HP calculators
- 15:38 – 24:38
Early Life, DJ Rush, and the Path to Neurology
Isaacson describes his teenage recording studio and his six-year combined medical program. He explains how his older brother's books and his uncle's Alzheimer's diagnosis pulled him toward neurology and Alzheimer's.
- •He ran a recording studio as a teen under the name DJ Rush
- •His older brother was a neurologist, and he read his brother's neuroanatomy books as a child
- •His uncle was diagnosed with Alzheimer's when Isaacson was in high school
- •He trained at Beth Israel Deaconess in Boston, where cognitive neurology began
- •He wanted to treat patients, not just describe phenomena
- 24:38 – 29:42
Miami, the Regenerates, and Moving to Cornell
Isaacson covers his years in Miami, where he played bass in a band and met his fiancée. He then explains how his patient-guide book and the pushback over the word prevention led him to Cornell, where the dean agreed to an Alzheimer's prevention clinic.
- •He met his fiancée while his band, The Regenerates, was playing in Miami
- •His 2011 book on Alzheimer's treatment and prevention drew criticism
- •Harvard would not let him use the term prevention
- •The Cornell dean questioned his age but approved the clinic after a 15-minute meeting
- •He argued that Alzheimer's starts in the brain decades before symptoms
- 29:42 – 38:03
How Alzheimer's Is Diagnosed and Distinguished from Other Dementias
Attia asks how Alzheimer's is diagnosed and how it differs from other dementias. Isaacson explains the clinical diagnosis, ruling out reversible causes, MRI findings, biomarkers, other dementias like Lewy body, and how depression can mimic dementia.
- •Diagnosis is traditionally clinical, based on progressive short-term memory loss affecting daily function
- •Cognitive aging differs from Alzheimer's because daily activities remain intact
- •Reversible causes like thyroid problems and B12 deficiency must be ruled out
- •MRI looks for atrophy, especially in the hippocampus, and biomarkers like amyloid and tau are now available
- •A depression-driven pseudodementia can look like memory loss
- 38:03 – 49:36
Cognitive Testing and the Rise of Brain Health Centers
Attia describes his experiment showing that commercial cognitive tests fail to detect impairment in drinkers. Isaacson explains his clinic's test battery and the six prevention centers now collaborating. They discuss the semantic fight over prevention versus risk reduction and the improving funding climate.
- •Attia had analysts take a commercial test while drinking, and their scores stayed flat
- •Most cognitive tests were validated in people with dementia, not early disease
- •Six prevention and brain health centers are now collaborating to harmonize measures
- •Reviewers pushed for risk reduction in place of prevention in a paper title
- •Isaacson says NIH funding has improved, with three grants now
- 49:36 – 58:21
Prevalence, Death from Alzheimer's, and Whether It Is Preventable
Isaacson and Attia discuss what high risk means, how prevalence estimates are made, and why death from Alzheimer's is hard to count. Isaacson describes Alzheimer's as a life course disease and says one in three cases may be preventable or delayable.
- •Estimates are about five million with dementia and 47 million with preclinical Alzheimer's
- •Alzheimer's is an indirect cause of death, which complicates death certificates
- •Isaacson uses the mnemonic AGE: age, genetics, environment
- •He believes about one in three cases may be preventable
- •Attia stresses that delaying onset buys time and optionality
- 58:21 – 1:12:39
APOE Genotypes, Polygenic Risk, and Deterministic Genes
They go through APOE2, 3, and 4 combinations and how the estimated risk of 4/4 has been revised downward. They cover polygenic risk, TNF alpha, deterministic early-onset genes, and genetic testing tools.
- •APOE3/3 is neutral risk, and about a quarter of the population carries at least one E4
- •Isaacson says fold-risk figures can't be pinned down without knowing a person's other genes
- •TNF alpha combined with APOE4 explained one family's early disease
- •Presenilin 1, presenilin 2, and the amyloid precursor protein gene cause true early-onset disease and account for under 1% of cases
- •They discuss genetic data from 23andMe and Prometheus
- 1:12:39 – 1:19:55
Why Women Face Higher Risk and the Question of Hormone Therapy
Isaacson explains why APOE4 matters and why he thinks women's higher risk is not just from living longer, pointing to the perimenopause transition and brain bioenergetics. They discuss multiple paths to Alzheimer's and where hormone replacement stands in his practice.
- •APOE4 plus age and female sex raises the likelihood of amyloid
- •Isaacson sees Alzheimer's as a mitochondrial, bioenergetic disease and thinks the perimenopause transition accelerates brain aging
- •Attia describes several paths to the same final common pathway
- •Isaacson says early hormone therapy for the first few years of perimenopause may be a good idea but the evidence is hazy
- •He does not prescribe hormones himself
- 1:19:55 – 1:29:28
Precision Medicine, MTHFR, and the ABCs of Prevention
Isaacson explains his clinic's registry and the MTHFR and homocysteine story, then lays out the ABCs: anthropometrics, biomarkers, and cognitive function. They also cover the methods paper and the free ALZU education site.
- •The registry stratifies patients by APOE and MTHFR and tracks responses to a lifestyle program
- •B vitamins help only when homocysteine is high, and optimized omega-3s matter
- •The methods paper and the free alzU.org course for the public and clinicians
- •ABCs: anthropometric, biomarkers (cholesterol, inflammation, metabolism, nutrition), cognitive function
- •Triangulating A, B, and C guides personalized decisions
- 1:29:28 – 1:36:16
Funding Prevention Research and the Case for Precision Medicine
Attia makes a plea for funding prevention research and describes the portfolio imbalance. Isaacson explains how modest funds would improve his biomarkers and data analysis. They discuss why personalized plans improve adherence and how the free website scales.
- •Treatment pharmacology for Alzheimer's has a very low success rate, according to Attia
- •The program has spent about $8 million in five years, mostly philanthropy
- •About $75,000 more would have allowed better omega-3 biomarkers
- •Personalized plans improve results and reinforce behavior
- •The free website reaches far more people than the clinic can see
- 1:36:16 – 1:54:00
Metabolism, Cognitive Domains, Statins, Omega-3s and Theracurmin
Isaacson discusses the metabolism of Alzheimer's, how cognitive domains map onto biomarkers, and the debate with amyloid-focused leaders. They cover his lipid targets and caution about statins in certain people, the timescale of omega-3 effects, and Theracurmin.
- •Isaacson believes Alzheimer's is largely a metabolic disease
- •Clinical patterns link lipids to executive function and visceral fat to memory
- •He is pro-statin but against one-size-fits-all, citing APOE4 and sex differences
- •DHA effects take years, so short studies may miss them
- •Theracurmin showed less amyloid in a small study, but Isaacson says not everyone needs it
- 1:54:00 – 2:11:42
Five No-Regret Moves: Education, Numbers, Exercise, Blood Pressure and Nutrition
Attia poses a cocktail-party scenario and Isaacson gives his priorities: learn about brain health, know your numbers, and exercise. He also discusses alcohol, blood pressure control from SPRINT-MIND, nutrition, fasting, stress, and sleep.
- •Education via alzU.org and knowing your numbers come first
- •Exercise is the top lever, with a mix of aerobic and strength training and attention to intensity
- •Alcohol evidence is murky, so Isaacson hedges toward less
- •SPRINT-MIND showed a 19% reduction in mild cognitive impairment with tighter blood pressure control
- •Nutrition, low carbs, leafy greens, 16-hour fasting, stress reduction and sleep also matter
- 2:11:42 – 2:24:31
Incidence vs Prevalence, Cognitive Reserve, and Closing Thoughts
They discuss why prevalence is rising even as incidence is falling, and how lifestyle and awareness each contribute. Isaacson explains cognitive reserve, education, music, and social support, and the episode closes with a call for philanthropic support.
- •Incidence is coming down while prevalence rises with an aging population
- •Isaacson attributes the change to a combination of awareness and lifestyle factors
- •Educational attainment and music build cognitive reserve, though decline can be sharper once reserve fails
- •Loss of a caregiving spouse can accelerate decline
- •Attia praises Isaacson's work and urges funding of prevention research
